Stockscreener 앱 받기
94.69
0.21%
-0.09
전일 마감가:
$94.60
열려 있는:
$95.08
하루 거래량:
27,899
Relative Volume:
0.06
시가총액:
$4.49B
수익:
$291.49M
순이익/손실:
$-308.55M
주가수익비율:
-20.90
EPS:
-4.53
순현금흐름:
$-168.02M
1주 성능:
-3.05%
1개월 성능:
+3.17%
6개월 성능:
+20.84%
1년 성능:
+59.51%
1일 변동 폭
$94.24
$95.50
1주일 범위
$90.86
$97.81
52주 변동 폭
$59.09
$105.00
Axsome Therapeutics Inc Stock (AXSM) Company Profile
명칭
Axsome Therapeutics Inc
전화
(212) 332-3241
주소
ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK
AXSM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| AXSM | 94.57 | 4.49B | 291.49M | -308.55M | -168.02M | -4.53 |
| VRTX | 447.03 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.54 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.40 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.40 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.67 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-03 | 개시 | Wells Fargo | Overweight |
| 2024-08-06 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-07-22 | 개시 | Needham | Buy |
| 2024-04-29 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-06 | 개시 | UBS | Buy |
| 2024-01-25 | 개시 | RBC Capital Mkts | Outperform |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-08-08 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-01-05 | 개시 | Piper Sandler | Neutral |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2022-09-07 | 재개 | Mizuho | Buy |
| 2021-08-10 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-10 | 개시 | Berenberg | Buy |
| 2021-01-08 | 개시 | Jefferies | Buy |
| 2020-12-16 | 개시 | Mizuho | Buy |
| 2020-09-29 | 개시 | BofA Securities | Underperform |
| 2020-09-10 | 개시 | Morgan Stanley | Overweight |
| 2020-04-28 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-14 | 개시 | Cowen | Outperform |
| 2019-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-17 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-16 | 재확인 | Guggenheim | Buy |
| 2019-10-16 | 개시 | Guggenheim | Buy |
| 2019-09-18 | 개시 | William Blair | Outperform |
| 2019-05-28 | 개시 | SunTrust | Buy |
| 2019-05-23 | 재확인 | H.C. Wainwright | Buy |
| 2019-04-08 | 개시 | SVB Leerink | Outperform |
| 2019-03-15 | 재확인 | H.C. Wainwright | Buy |
| 2016-10-03 | 재개 | Brean Capital | Buy |
| 2015-12-15 | 개시 | Cantor Fitzgerald | Buy |
| 2015-12-14 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Axsome Therapeutics Inc 주식(AXSM)의 최신 뉴스
Axsome Therapeutics' SWOT analysis: strong pipeline, sales growth boost stock outlook - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) Rating Increased to Hold at StockNews.com - MarketBeat
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up - MSN
Royce & Associates LP Has $2.02 Million Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
First Turn Management LLC Trims Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Is It Too Late to Buy Viking Therapeutics Stock? - The Motley Fool
FY2024 EPS Estimates for AXSM Increased by Leerink Partnrs - MarketBeat
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript - AOL
Axsome Therapeutics Inc (AXSM) Quarterly 10-Q Report - Quartzy
Axsome Advances Sleep Disorder Pipeline as Sunosi Prescriptions Increase in Q3 - Sleep Review
Equities Analysts Offer Predictions for AXSM FY2027 Earnings - MarketBeat
William Blair Issues Pessimistic Outlook for AXSM Earnings - MarketBeat
Axsome stock price target increased, rating held on strong sales - Investing.com
Axsome stock price target increased, rating held on strong sales By Investing.com - Investing.com UK
Axsome Therapeutics stock hits 52-week high at $98.61 By Investing.com - Investing.com Nigeria
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2024 Earnings Call Transcript - Insider Monkey
Robert W. Baird Raises Axsome Therapeutics (NASDAQ:AXSM) Price Target to $116.00 - MarketBeat
Earnings call: Axsome Therapeutics reports record quarterly revenue By Investing.com - Investing.com Australia
Versor Investments LP Acquires New Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics’ Strong Q3 Growth Amidst Strategic Expansions - TipRanks
Axsome: Q3 Earnings Snapshot - Houston Chronicle
Earnings call: Axsome Therapeutics reports record quarterly revenue - Investing.com
Axsome Therapeutics stock hits 52-week high at $98.61 - Investing.com India
Axsome shares rise as Guggenheim lifts target to $135 By Investing.com - Investing.com UK
Axsome Therapeutics Q3 Earnings: Stay For Near Term Catalysts, Then Sell (AXSM) - Seeking Alpha
Axsome Therapeutics (NASDAQ:AXSM) Reaches New 52-Week HighShould You Buy? - MarketBeat
A Closer Look at 10 Analyst Recommendations For Axsome Therapeutics - Benzinga
Axsome Therapeutics Inc earnings beat by $0.04, revenue topped estimates - Investing.com
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates - MSN
Axsome Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Axsome Therapeutics' (AXSM) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Truist maintains buy on Axsome with $150 target on strong Auvelity sales - Investing.com UK
(AXSM) Proactive Strategies - Stock Traders Daily
Privium Fund Management B.V. Grows Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Position Decreased by Lindbrook Capital LLC - MarketBeat
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 - GlobeNewswire
Axsome Therapeutics to Present Breakthrough CNS Data Across 3 Major Disorders at NEI 2024 | AXSM Stock News - StockTitan
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for - Yahoo Finance
Axsome Therapeutics (AXSM) to Release Earnings on Tuesday - MarketBeat
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Position Trimmed by abrdn plc - MarketBeat
Assenagon Asset Management S.A. Lowers Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat
Analysts Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) Target Price at $124.64 - MarketBeat
(AXSM) Trading Advice - Stock Traders Daily
Upcoming Opportunities in Hypersomnia Therapeutics Market: - openPR
Axsome Therapeutics' (NASDAQ:AXSM) investors will be pleased with their impressive 257% return over the last five years - Simply Wall St
Major Depressive Disorder Market Expected to Experience Major Growth by 2034, According to DelveInsight | Takeda, Otsuka Pharma, AbbVie, SAGE Therapeutics, Forest Laboratories, Axsome Therapeutics - The Globe and Mail
Major Depressive Disorder Market Expected to Experience Major - openPR
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024 - The Manila Times
Axsome Therapeutics Inc (AXSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Axsome Therapeutics Inc 주식 (AXSM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Saad Mark E | Director |
Sep 11 '24 |
Option Exercise |
3.67 |
11,016 |
40,429 |
21,018 |
| Saad Mark E | Director |
Sep 11 '24 |
Sale |
91.31 |
11,016 |
1,005,871 |
10,002 |
0.42%
0.16%
자본화:
|
볼륨(24시간):